Showing 7571-7580 of 9758 results for "".
- FDA Grants Soligenix Fast Track Designation for SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphomahttps://practicaldermatology.com/news/fda-grants-soligenix-fast-track-designation-for-sgx301-for-first-line-treatment-of-cutaneous-t-cell-lymphoma/2459030/Soligenix, Inc.’s SGX301 (synthetic hypericin) development program for the first-line treatment of cutaneous T-cell lymphoma (CTCL) received "fast track" designation from the FDA. Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life-thre
- Suneva Medical's Bellafill Approved to Treat Acne Scarshttps://practicaldermatology.com/news/suneva-medicals-bellafill-approved-to-treat-acne-scars/2459034/Suneva Medical, Inc.'s Bellafill® is now the only filler on the market approved for the treatment of acne scars. FDA granted approval for Bellafil
- Revance Therapeutics Initiates BELMONT Phase 2 Active Comparator Trial of Injectable RT002https://practicaldermatology.com/news/revance-launches-phase-2-belmont-study/2459035/Specialty biopharmaceutical company Revance Therapeutics, Inc. has initiated the BELMONT trial, a Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and
- Modernizing Medicine, Inc. Acquires Aesyntix Health, Inc.https://practicaldermatology.com/news/modernizing-medicine-inc-acquires-aesyntix-health-inc/2459037/Modermizing Medicine, Inc., creator of the Electronic Medical Assistant® (EMA™), completed an acquisition of Aesyntix Health, Inc. on
- FDA Grants Bristol-Myers Squibb's Opdivo Accelerated Approval for Melanomahttps://practicaldermatology.com/news/fda-grants-bristol-myers-squibbs-opdivo-accelerated-approval-for-melanoma/2459039/The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following Yervoy (ipilim
- Vivacare Launches "Find a Dermatologist" Directory with "Expert Opinion" Functionhttps://practicaldermatology.com/news/vivacare-launches-find-a-dermatologist-directory-with-expert-opinion-function/2459044/Vivacare has launched its new <a href="http://www.findadermatologist.com" target="_blank">Find a Dermatolog
- Pierre Fabre Dermatologie Receives the Prix Galien Award for Pharmaceutical Research for Hemangiolhttps://practicaldermatology.com/news/pierre-fabre-dermatologie-receives-the-prix-galien-award-for-pharmaceutical-research-for-hemangiol/2459047/Pierre Fabre Dermatologie, a subsidiary of Pierre Fabre Dermo-Cosmetics, was distinguished by the Prix Galien award (France) for Hemangiol, an oral pediatric propranolol solution specifically developed for some severe infantile hemangiomas. Hemangiol® was successively approved by Americ
- ArteFill Changes Name to Bellafillhttps://practicaldermatology.com/news/artefill-changes-name-to-bellafill/2459051/Suneva Medical, Inc.’s ArteFill dermal filler has been rebranded as Bellafill in the US. "We feel that the brand Bellafill better embodies the transformational outcomes this unique product can provide to our customers and th
- FDA Approves Valeant's Onexton Gel for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-valeants-onexton-gel-for-the-treatment-of-acne-vulgaris/2459053/The FDA approved Valeant Pharmaceuticals International, Inc.’s Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new d
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi